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Ambulatory arterial stiﬀness index (AASI) is a parameter obtained from ambulatory blood pressure monitoring (ABPM) that
correlates with clinical endpoints. The aim of this study was to compare AASI in nondiabetic hypertensive patients with and
without chronic kidney disease (CKD). Subjects with systemic arterial hypertension (SAH, n = 30) with normal renal function,
aged 40 to 75 years, were compared to hypertensive patients with CKD (n = 30) presenting estimated glomerular ﬁltration rate
(eGFR) <60mL/min by MDRD formula. ABPM was carried out in all patients. In CKD group, eGFR was 35.3 ± 2.8ml/min. The
mean 24-hour systolic and diastolic blood pressure (BP) was similar in both groups. AASI was signiﬁcantly higher in CKD group
(0.45 ± 0.03 versus 0.37 ± 0.02, P<0.0 5 ) ,p o s i t i v e l yc o r r e l a t e dt oa g e( r = 0.38, P<0.01) and pulse pressure (r = 0.43, P<0.01)
and negatively correlated to nocturnal BP fall (r =− 0.28, P = 0.03). These ﬁndings indicate the presence of stiﬀer vessels in CKD
hypertensive patients.
1.Introduction
Epidemiological and observational studies indicate hyper-
tension as a major cause of chronic kidney disease (CKD)
[1]. In fact, hypertension and CKD are strongly connected
because hypertension is both a cause and a consequence of
CKD [2]. Hypertensive patients with CKD present higher
morbidity and mortality rates when compared with those
with normal renal function [3, 4]. Additionally, high blood
pressure is a predictor of decline of glomerular ﬁltration
rate (GFR), and conversely, adequate blood pressure control
contributes to preserve renal function [5–7].
Vascular changes are commonly observed in CKD
patients, including reduced arterial elasticity observed in pa-
tients with end-stage renal disease [8, 9]. Fibroelastic intimal
thickening,increasedextracellularmatrix,enhancedcollagen
density, and vascular calciﬁcation seem to contribute to
stiﬀer arteries in CKD patients [10, 11]. It has been
demonstrated that vascular stiﬀness may predict adverse
cardiovascular outcomes [12, 13]. Current gold standard
f o rv a s c u l a rs t i ﬀness evaluation is the pulse wave velocity
(PWV) which requires complex equipment and therefore
is not commonly used in clinical practice [14]. Recently, a
new parameter named ambulatory arterial stiﬀness index
(AASI) was proposed for this evaluation [15, 16]. This index
isderivedfromtheregressionslopeofthediastoliconsystolic
blood pressure, using all of the readings during ambulatory
blood pressure monitoring (ABPM).
It has already been reported that AASI presents good
correlation with target organ damage and glomerular ﬁltra-
tion rate (GFR) in essential hypertension [17–20]. Moreover,
AASI may also correlate with cardiovascular events and
mortality [21, 22]. On the other hand, there have been few
studies investigating this index in hypertensive patients with
diﬀerent stages of CKD. The aim of our study was to evaluate
theAASIinnondiabetic hypertensivepatientswithCKDand
in those with normal renal function.2 International Journal of Hypertension
2. Methods
A case-control study involving 60 consecutive patients with
primary hypertension was carried out in our institution.
Thirty patients were recruited from the CKD outpatient
clinic. Hypertensive patients with CKD, aged 40 to 75 years
andestimatedglomerularﬁltrationrate(eGFR)<60mL/min
by the Modiﬁcation of Diet in Renal Disease (MDRD) equa-
tion [23], were included (CKD group). Other 30 patients
matched by age (±2 years) and gender with the CKD pa-
tients were selected from the hypertension outpatient clinic
at the same institution. These patients presented systemic
arterial hypertension (SAH group) and serum creatinine
less than 1mg/dL. Exclusion criteria were diabetes melli-
tus, hypertriglyceridemia (>400mg/dL), urinary albumin-
to-creatinine ratio (UACR) >1000mg/g, acute renal failure,
renal replacement therapy, regular use of anti-inﬂammatory
drugs, and history of myocardial infarction or cerebrovascu-
lar disease in the last 6 months. The local Ethics Committee
has previously approved the study protocol, and all partici-
pants gave written informed consent.
2.1. Blood Pressure Measurements. Oﬃce blood pressure was
obtained using an electronic device (model HEM-705CP,
Omron Healthcare Inc., IL, USA) and an appropriate sized
cuﬀ.Patientswereseatedfor30minutesbeforemeasurement
and refrained from smoking and caﬀeine ingestion in this
period of time. Three readings, one minute apart, were done,
and the average of these measurements was deﬁned as the
patient clinic blood pressure. The patients underwent 24-
hour ABPM in nondominant arm with SpaceLabs 90207
monitor (Spacelabs Inc., Redmond, WA, USA), validated by
the British Hypertension Society and the Association for
the Advancement of Medical Instrumentation protocol [24].
Readings were taken every 20 minutes during the day and
every 30 minutes at night. The patients recorded their sleep
and wake times during the monitoring. ABPM was consid-
ered adequate if >70% of measurements were successfully
obtained. The percentage decline in nocturnal blood pres-
sure was calculated as follows for systolic (SBP) and diastolic
(DBP) blood pressures: percentage decline in nocturnal
blood pressure = (daytime blood pressure−night-time blood
pressure) ∗ 100/daytime blood pressure. The AASI was
calculated from 1 minus the regression slope of diastolic
pressure on systolic blood pressure. The slope was not forced
through the origin.
2.2. Blood and Urine Samples Collection. Fasting venous
blood was collected from participants to measure total chol-
esterol, triglycerides (TG), high-density lipoprotein choles-
terol (HDL-C), glucose, creatinine (enzymatic method), and
uric acid. The low-density lipoprotein cholesterol (LDL-C)
level was calculated by the Friedewald formula (8). eGFR
was assessed by modiﬁed MDRD equation: eGFR = 0.741
× 175 × Cr−1.154× age−0.203(× 0.742 if female). C-reactive
protein (nephelometry, BN II, Siemens AG Inc, Munich,
Germany)andmorning urinary spotalbuminandcreatinine
(nephelometry, Immage, Beckman Coulter Inc, Fullerton,
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Figure 1: Percentage of nocturnal blood pressure fall patterns as
dipper, nondipper, and reverse dipper in chronic kidney disease
(CKD) and systemic arterial hypertension (SAH) groups.
CA, USA) were also measured. The lower detection limit for
C-reactive protein was 0.20mg/L. Values for microalbumin-
uria were considered normal up to 30mg/g creatinine.
2.3. Statistical Analyses. Data are presented as mean ±
standard error of mean (SEM). For database management
and statistical analyses, we used GraphPad Prism software,
version5.0(GraphPadSoftwareInc.,CA,USA).Chi-squared
test (for 2 × 3 tables) or Fisher’s exact test (for 2 × 2 tables)
and Student’s t-test were used to compare proportions and
means, respectively. Pearson’s correlation coeﬃcients were
used to explore associations between examined continuous
variables with parametric distribution. Statistical signiﬁcan-
ce was determined by α-level of 0.05 on two-sided tests.
3. Results
Baseline clinical characteristics did not diﬀer between the
groups. As expected, hemoglobin was signiﬁcantly lower and
serum creatinine and uric acid were signiﬁcantly higher in
CKD group (Table 1). Mean eGFR by MDRD in the CKD
group was 35.3 ± 2.8mL/min. C-reactive protein and UACR
were signiﬁcantly higher in CKD group (Table 1).
The mean oﬃce and ambulatory blood pressure readings
were similar in both groups (Table 2), although CKD
patientsneededtousemoreantihypertensivedrugs(2.7±0.2
versus 2.2 ± 0.1, P = 0.0398) to obtain blood pressure
control.WhenCKDwascomparedtoSAHgroupconcerning
antihypertensive treatment, there was no signiﬁcant diﬀer-
ence for diuretics (60% versus 70%), angiotensin converting
enzyme inhibitors/angiotensin receptor blockers (86% ver-
sus 77%) and beta blockers (40% versus 37%). However,
use of calcium channel antagonists was signiﬁcantly more
common in CKD patients (47% versus 23%, P<0.01).
The mean nocturnal systolic blood pressure fall was
lower than 10% in both groups (4.0 ± 1.5% in CKD versus
7.6 ±1.1% in SAH, P = 0.0588). There were 40% of dipperInternational Journal of Hypertension 3
Table 1: Demographic, anthropometric, and laboratory data of hypertensive patients in both groups.
Variable SAH group CKD group P value
Age (years) 62.8 ±1.76 3 .2 ±1.7 0.8786
Men, n (%) 18 (60) 18 (60) 1.0000
Black, n (%) 4 (13) 7 (23) 0.3251
Current smokers, n (%) 5 (17) 4 (13) 0.7232
Previous cerebrovascular disease, n (%) 2 (7) 2 (7) 1.0000
Dyslipidemia, n (%) 14 (47) 13 (43) 0.7091
BMI (kg/m2)2 7 .4 ±0.82 6 .4 ±0.8 0.3856
Waist-to-hip ratio 0.93 ±0.01 0.92 ±0.01 0.6881
Hemoglobin (g/dL) 13.9 ±0.21 2 .5 ±0.2 <0.0001
Glucose (mg/dL) 95.8 ±11.19 8 .7 ±8.9 0.2645
Creatinine (mg/dL) 0.82 ±0.17 2.26 ±0.78 <0.0001
eGFR (mL/min) 92.8 ±4.83 5 .3 ±2.8 <0.0001
Sodium (mg/dL) 139 ±0.4 137 ±3.4 0.6317
Potassium (mg/dL) 4.3 ±0.09 4.8 ±0.08 0.0927
Uric acid (mg/dL) 6.0 ±2.08 .4 ±1.8 <0.0001
Triglycerides (mg/dL) 164 ±100 232 ±149 0.0737
Total Cholesterol (mg/dL) 205 ±36 200 ±41 0.6355
LDL-cholesterol (mg/dL) 120 ±39 106 ±33 0.1489
HDL-cholesterol (mg/dL) 51 ±24 39 ±10 0.0199
C-Reactive protein (mg/L) 2.6 ±0.66 .4 ±1.7 0.0338
UACR (mg/g) 19 ±5 367 ±90 0.0002
LVH in ECG, n (%) 1 (4) 4 (13) 0.2216
Data presented as mean ± SEM or n (%). SAH, systemic arterial hypertension; CKD, chronic kidney disease; BMI, body mass index; eGFR, estimated
glomerular ﬁltration rate by MDRD equation; LDL, low-density lipoprotein; HDL, high-density lipoprotein; UACR, urinary albumin-creatinine ratio; LVH,
left ventricular hypertrophy; ECG, electrocardiogram.
Table 2: Oﬃce and ambulatory blood pressure parameters of hypertensive patients with normal and impaired renal function.
BP parameters SAH group CKD group P value
AASI, units 0.37 ±0.02 0.45 ±0.03 0.0400
Oﬃce systolic BP, mmHg 149 ±3 145 ± 4 0.4452
Oﬃce diastolic BP, mmHg 87 ±28 5 ±2 0.5121
Controlled oﬃce BP, n (%) 15 (50) 10 (33) 0.2949
24 h systolic BP, mmHg 131 ±3 133 ± 3 0.6172
24 h diastolic BP, mmHg 81 ±27 9 ±2 0.6004
2 4hP u l s eP r e s s u r e ,m m H g 5 0±25 4 ±2 0.2034
Controlled 24 h BP, n (%) 14 (47) 14 (47) 1.0000
White coat eﬀect, n (%) 6 (20) 3 (10) 0.2859
D a y t i m es y s t o l i cB P ,m m H g 1 3 4±3 135 ± 3 0.8732
Daytime diastolic BP, mmHg 83 ±28 1 ±2 0.5507
Nocturnal systolic BP, mmHg 124 ±3 129 ± 3 0.2707
Nocturnal diastolic BP, mmHg 75 ±27 4 ±2 0.9644
Systolic nocturnal fall, % 7.6 ±1.14 .0 ±1.5 0.0588
Diastolic nocturnal fall, % 10.7 ±0.18 .6 ±0.2 0.2945
Data are expressed as mean ± SEM or n (%). AASI, ambulatory arterial stiﬀness index; SAH, systemic arterial hypertension; CKD, chronic kidney disease; BP,
blood pressure.4 International Journal of Hypertension
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Figure 2: Plots of ambulatory arterial stiﬀness index on age (a), pulse pressure (b), and systolic nocturnal blood pressure fall (c).
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Figure 3: Ambulatory arterial stiﬀness index (AASI) according to
estimated glomerular ﬁltration rates (eGFR). Data are presented as
mean ± SEM. ∗P<0.05 versus other groups.
patients, 50% of nondipper, and 10% of reverse dipper
in SAH group. On the other hand, CKD group presented
30% of dipping pattern, 40% nondipping, and 30% reverse
dipping (Figure 1). Pulse pressure was not diﬀerent between
CKD and SAH groups (54 ± 2v e r s u s5 0± 2mmHg,
P = 0.20).
The AASI index was signiﬁcantly higher in CKD patients
when compared with SAH group (0.45 ± 0.03 versus 0.37 ±
0.02, P = 0.04). Correlation tests showed that AASI was
positively related to age (r = 0.38, P<0.01), pulse pressure
(r = 0.43, P<0.01) and inversely related to nocturnal blood
pressure fall (r =− 0.28, P = 0.03) (Figure 2). AASI did not
correlate to UACR, serum creatinine, or eGFR. However,
when eGFR was analyzed among all patients, those with
eGFR less than 30mL/min had higher AASI (Figure 3).
4. Discussion
The results of our study demonstrate that hypertensive
patients with CKD presented a higher AASI when compared
to those with normal renal function. Supporting the concept
thatAASIisamarkerofarterialstiﬀness,Lietal.describedits
correlation with pulse wave velocity, central and peripheral
augmentation indexes [15]. Moreover, in a cohort of 11,291
patients, Dolan et al. showed that AASI carried prognostic
information, as it was a predictor of stroke and cardiac death
[16]. In a Japanese study, Kikuya et al. also observed that
AASI predicted cardiovascular and stroke mortality over and
beyond pulse pressure [25]. Muxfeldt et al. demonstrated
that AASI is a predictor of cardiovascular morbidity and
mortality in 547 patients with resistant hypertension [21].
Furthermore, some research groups have already reported
that AASI presents good reproducibility, with repeatability
coeﬃcients close to 60% [26, 27]. Criticizers say that this
index is dependent on pulse pressure and dipping pattern
and do not provide new information [28, 29]. Schillaci et al.
studied 515 untreated hypertensive patients and found that
AASI was strongly dependent on the degree of nocturnal
blood pressure fall and only weakly related to pulse wave
velocity [28]. Similar results were found by Baumann et al.
with 112 German hypertensive patients [29].
Some authors have studied the relationship between
AASI and renal function among hypertensive patients. Ratto
et al. showed that AASI was positively related to urinary
albumin excretion and negatively related to estimated crea-
tinine clearance in a population of 168 patients with recently
diagnosed hypertension and without drug treatment [30].
Mul` e et al. studied 142 hypertensive patients without drug
treatment and with serum creatinine less than 1.5mg/dL
and demonstrated that patients with high AASI presented
lower GFR [17]. This paper also suggested that AASI was a
better predictor of GFR decline than 24 h pulse pressure. In
554 hypertensive patients with and without drug treatment,
Garcia-Garcia et al. observed that AASI correlates with
eGFR, carotid intima-media thickness, and Cornell voltage-
duration product [20].
Ageing is an important factor for arterial stiﬀening.
Elderly people are predisposed to lose arterial elastic laminae
and increase collagen deposits in vascular wall [10, 31]. This
way, assuming AASI as a marker of vascular stiﬀness, the
relationship between AASI and age is expected. Interestingly,
CKD patients tend to have stiﬀer vessels when compared to
age-andblood-pressure-matchedpatientswithnormalrenal
function [31, 32]. Beyond traditional risk factors, such as
hypertension and dyslipidemia, uremia seems also play a role
to this ﬁnding. Mineral metabolism alterations and arterial
calciﬁcation are probably relevant mechanisms [10, 33]. ThisInternational Journal of Hypertension 5
may be one hypothesis to explain why AASI was higher
in CKD than in SAH group despite similar oﬃce and
ambulatory blood pressure measurements in the present
study. Moreover, patients with the lowest eGFR (stage 4,
according to the American National Kidney Foundation [4])
presented higher AASI.
Pulse pressure and nocturnal blood pressure fall are
two parameters from ABPM that correlate with arterial
stiﬀness [34, 35]. Lekakis et al. and Jerrard et al. showed
that hypertensive patients with nondipper pattern presented
stiﬀer vessels when measured by pulse wave velocity, suggest-
ing a relationship between blunted nocturnal blood pressure
fall and reduced arterial elasticity [35, 36]. These ﬁndings
corroborate with our study, since nocturnal blood pressure
fall and pulse pressure were correlated with AASI. Indeed,
AASI was diﬀerent between groups despite similar pulse
pressure and dipper status. This emphasizes the importance
of calculating AASI after ABPM.
The present study has limitations considering the small
samplesize.Moreover,itwasnotprospectiveandnotfocused
on clinical outcomes. However, our data strongly implies
the value of AASI as a noninvasive tool for hemodynamic
evaluation of CKD patient and reinforces the role of ABPM
in hypertensive patients with renal dysfunction. Increased
AASI might be one of the pathophysiological changes
observedinCKDpatientsbeforetheprogressiontoendstage
renal disease. More studies are needed to support the clinical
usefulnessofthisparameter,butweproposethatthesoftware
for ABPM analysis should include AASI value as a marker of
cardiovascular risk assessment in the near future.
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